HanesBrands Inc
Change company Symbol lookup
Select an option...
HBI HanesBrands Inc
TMKR Tastemaker Acquisition Corp
SPY SPDR® S&P 500 ETF Trust
STOR STORE Capital Corp
PIPP^ Pine Island Acquisition Corp
PEP PepsiCo Inc
$NASI5000LMN NASDAQ Asia Cnsmr Svcs Large Mid Cap
PNM PNM Resources Inc
CBLAQ CBL & Associates Properties Inc
APLE Apple Hospitality REIT Inc

Consumer Discretionary : Textiles, Apparel & Luxury Goods | Small Cap Value
Company profile

Hanesbrands Inc. is a marketer of basic innerwear and activewear apparel in the Americas, Europe, Australia and Asia/Pacific under apparel brands, such as Hanes, Champion, Maidenform, DIM, Bali, Playtex, Bonds, JMS/Just My Size, Nur Die/Nur Der, L'eggs, Lovable, Wonderbra, Gear for Sports and Berlei. The Company operates through three segments: Innerwear, Activewear and International. The Innerwear segment focuses on core apparel products, such as intimate apparel, men's underwear, women's panties, children's underwear, socks and hosiery. The Company operates in the activewear market through its Champion, Hanes and JMS/Just My Size brands. The International segment includes products that primarily span across the innerwear and activewear segments.

Closing Price
Day's Change
0.76 (4.12%)
B/A Size
Day's High
Day's Low

10-day average volume:

Analysts say Vertex's stock is under pressure after drug development failure

7:31 am ET October 15, 2020 (MarketWatch)

Shares of Vertex Pharmaceuticals Inc. (VRTX) were down 9.8% in premarket trading on Thursday, the day after the drug maker said it had stopped development (http://www.marketwatch.com/story/vertex-stock-falls-after-protein-deficiency-drug-development-stopped-11602709656) of an experimental therapy aimed at treating Alpha-1 antitrypsinase deficiency, which can cause lung and liver disease. Vertex cited the therapy's safety and pharmacokinetic profile of VX-814 as observed in a Phase 2 clinical trial. SVB Leerink's Geoffrey Porges told investors on Wednesday he now expected Vertex's stock to be under pressure, and that "investors are likely to question whether the heralded Vertex research capability is really validated beyond" cystic fibrosis drugs. (All four of Vertex's Food and Drug Administration-approved products treat cystic fibrosis.) Paul Matteis, a Stifel analyst, wrote in a note to investors on Thursday that the news was "a negative surprise" and it will pressure the stock. However, he also noted that development of a "structurally distinct" back-up compound is underway. Vertex's stock is up 24.0% for the year, while the S&P 500 has gained 7.9%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

October 15, 2020 07:31 ET (11:31 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.